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Ascites is the most common complication of cirrhosis and its development is a 
sign of significant portal hypertension [1]. It becomes clinically detectable when 
in excess of 1.5 lt. Ascites in cirrhosis is the result of a vicious cycle involving 
arterial splanchnic vasodilation, decreased effective blood volume despite a 
compensatory increase in cardiac output, renal vasoconstriction with resulting 
sodium retention and finally extracellular fluid retention [2]. Systemic 
inflammation can exacerbate portal hypertension, contribute to the development 
of ascites and impair prognosis. 
Detection of ascites should prompt medical history and clinical examination, 
laboratory investigations including full liver screen, a diagnostic tap 
(paracentesis) and abdominal imaging. Ascitic fluid should be sent for cell count, 
total protein, albumin, cytology and cultures in all patients and for LDH, 
cholesterol and amylase in selected cases. New onset of ascites in a patient with 
cirrhosis should prompt abdominal imaging to exclude portal vein thrombosis or 
hepatocellular carcinoma. A serum to ascites albumin gradient (SAAG) ≥1.1 g/dl 
has 97% accuracy for diagnosis of ascites due to portal hypertension. Patients 
with a total protein of <1.5 g/dl and advanced liver disease should be considered 
for primary prophylaxis of spontaneous bacterial peritonitis (SBP) [3]. Usual 
clinical practice is to reserve primary prophylaxis for selected patients in the 
transplant waiting list. A neutrophil count (cut-off 250/µl) should be obtained in 
each diagnostic tap to diagnose SBP. Patients with SBP should be treated 
empirically with a third generation cephalosporin in community-acquired 
infections or according to the local microbiological resistance profile in 
nosocomial infections (until culture results become available) together with 
albumin infusions (1.5 g/Kg on day 1 and 1 g/Kg on day 3) [4, 5]. Once the 
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episode is resolved, secondary prophylaxis should be instigated; the choice of 
antibiotic depends on the bacterial resistance in the ascites and is a quinolone in 
uncomplicated cases [6].  
Once cirrhosis is confirmed as the cause of ascites, etiological treatment for the 
underlying liver disease should be considered and initiated as soon as possible 
as the patient might re-compensate with successful treatment (indicatively 
antivirals for hepatitis B, alcohol cessation in alcohol-related cirrhosis). 
Angiotensin-converting enzyme inhibitors and non-steroidal anti-
inflammatories should be stopped and aminoglycosides should be avoided as 
they can worsen ascites and/or induce renal failure. The initial treatment of 
mild/moderate ascites includes moderate sodium restriction to 80-120 
mmol/day and the use of diuretics [6]. Spironolactone (100 mg/day) is the 
diuretic of choice, with or without 40 mg/day of furosemide. Spironolactone 
monotherapy is recommended for first presentation of ascites, while 
combination with furosemide is preferred in recurrent ascites [6]. Diuretic 
treatment should be monitored and tailored according to weight loss (max 
800g/day), kidney function and serum electrolytes. Random urinary electrolytes 
can be used to tailor and adjust diuretic treatment. Diuretics can be increased to 
a maximum dose of 400 mg/day and 160 mg/day for spironolactone and 
furosemide, respectively. Complications of diuretic treatment include acute 
kidney injury, electrolyte disorders, encephalopathy, muscle cramps and tender 
gynaecomastia; therefore patients should be monitored closely particularly 
when treatment is initiated or following dose increases. A 50% increase of 
creatinine values in 7 days or an absolute increase by >26.5 μmol/L (0.3 mg/dL) 
in 48 hours should prompt temporary discontinuation of diuretics or a dose 
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reduction [6].  Diuretics should also be discontinued if severe hyponatraemia 
develops (<120 mmol/L). 
Refractory ascites is defined as persistence of ascites despite sodium restriction 
and maximum dose or maximally tolerated dose of diuretics and is associated 
with a one-year mortality of over 40% [7]. Patients with refractory ascites, 
history of SBP or hepatorenal syndrome should be referred and worked up for 
liver transplantation if eligible. Large volume paracentesis (LVP) aiming to 
remove all fluid is the initial treatment of patients with large, recurrent or 
refractory ascites. No correction of coagulation is required for a paracentesis. In 
order to prevent the occurrence of circulatory dysfunction and renal 
impairment, 8 g of albumin should be administered intravenously after LVP for 
every liter of fluid removed if the total paracentesis volume is >5 liters [8].  
The use of non-selective beta-blockers (NSBB) in patients with refractory ascites 
is controversially discussed. While NSBBs are associated with marked 
hypotension in patients with SBP, they seem to reduce mortality of patients with 
acute-on-chronic liver failure [9] or those with ascites waiting for liver 
transplantation [10]. Judicious use of NSBBs is therefore recommended in order 
to avoid hypotension and renal impairment. 
TIPS is an alternative for recurrent or refractory ascites and can improve 
survival probability in eligible patients [11]. The presence of overt 
encephalopathy, serum bilirubin >5mg/dL, portal vein thrombosis and cardiac 
insufficiency should be ruled out beforehand. In terms of laboratory parameters, 
a combination of a bilirubin level below 50 umol/L/3mg/dL and platelet count 
>75,000/mm3 is associated with best outcomes [12]. If the patient is ineligible 
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for TIPS or liver transplantation, then clinical trials, such as for the alpha pump 
system, are available in selected centers. 
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